Study Stopped
Not yet meeting Health Canada's requirements for Clinical Trials
Effect of Hypertonic Saturated Saline Mouth Rinse on Covid-19 Virus in Vivo.
Effect of Prolonged Mouth Rinse With Hypertonic Saturated Saline Solution on the Naso-Pharyngeal Viral Load of Covid-19 Virus in Vivo.
1 other identifier
interventional
N/A
1 country
1
Brief Summary
Sars-Cov2 virus is transmitted through the respiratory route and by direct contact with contaminated surfaces and subsequent contact with nasal, oral or ocular mucosa. Many studies have found that the oral cavity and specifically the saliva may be a high-risk route for SARS-CoV-2 infection. Thus, strategies reducing salivary viral load could contribute to reduce the risk of transmission. Furthermore, studies have shown that SARS-CoV persists for two days in oral mucous membranes before its diffusion to the lower respiratory tract. This offers an interesting preventive and therapeutic window of opportunity for the control of this disease. In addition, Naso-pharyngeal viral load was linked with lung disease severity in a study of 12 patients with pneumonia.\*\*. Some current studies around the world, as listed on ClinicalTrials.gov, are testing the effect of some common mouth rinses/gargles on the Covid-19 viral load, including Chlorhexidine gluconate, Hydrogen peroxide Povidone Iodine, Saline (1.102% w/v, slightly hypertonic) and Alcohol. This study aims to test whether Prolonged Hypertonic Saline Mouth Rinse would reduce/eliminate\*\*\* the viral load in the Oro- Naso-Pharyngeal cavity, and could therefore be used as a strategy to reduce transmission risk in clinical and social settings. The investigator hypothesizes that COVID-19-positive participants who use Hypertonic Saline Prolonged Rinse treatment will have an reduction/elimination of their Covid viral load, will develop a negative Covid test 7 days after intervention completion and will improve their clinical symptoms, potentially reducing lung disease severity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Jul 2021
Shorter than P25 for phase_2 covid19
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 11, 2021
CompletedFirst Posted
Study publicly available on registry
April 13, 2021
CompletedStudy Start
First participant enrolled
July 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2021
CompletedJuly 25, 2022
July 1, 2022
3 months
April 11, 2021
July 21, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants with Negative Covid PCR test results
The number of Negative PCR tests post intervention will be compared between both the Active group and the Control group. The Hypertonic Saturated Mouth Rinse intervention will be considered effective in reducing/eliminating Covid presence in the Oro-Nasopharyngeal area if the PCR Covid tests performed 7 days post termination of the study have more statistically-significant negative results in the Active group than in the Control group..
7 days
Secondary Outcomes (1)
Number of Participants with Change in Clinical Symptoms
7 days
Study Arms (2)
Hypertonic Saturated Saline Mouth Rinse Active Arm
ACTIVE COMPARATORThe Active Rinse is a 25 ml of Hypertonic Saturated Saline solution made by mixing 10 grams of Sodium Chloride (Table Salt) in 25 ml of Tap water with some salt crystals deposited.
Plain Water Control Arm
PLACEBO COMPARATORThe Control Rinse is a 25 ml of Plain Tap Water.
Interventions
Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.
Each Patient of this groups will be asked to keep the water still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the water will be spit out. The process will be done twice a day for 2 days.
Eligibility Criteria
You may qualify if:
- Tested positive for Covid in the past 7 days
- Have the ability to perform mouth rinse twice daily for 2 days and to undergo Covid testing by Oro or Naso-Pharyngeal swabs.
- No need for a ventilator for oxygenation support
- Can understand and read English
- Lives in Alberta Canada
You may not qualify if:
- Requiring mechanical ventilation
- Unable to perform mouth rinses twice times daily for 2 days
- Patients that are tested negative for COVID-19
- Patients who have been eating or drinking within an hour before or after each session
- Use of an antiseptic mouthwash within 7 days prior or after the study
- Patient who are intubated or too sick to give consent for the study.
- Not able to speak in English or lacking the decision-making capacity to consent for study.
- Inability to comply with protocol
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rafik Batroussylead
Study Sites (1)
Rafik Batroussy
Calgary, Alberta, Canada
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Rafik Batroussy, BSc.Pharm.
Independent
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
April 11, 2021
First Posted
April 13, 2021
Study Start
July 1, 2021
Primary Completion
October 1, 2021
Study Completion
December 1, 2021
Last Updated
July 25, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will not share